Haemonetics
HAE· Manufacturing· Fiscal year ends in April
CEO pay in FY2023
Christopher A. Simon is the CEO of Haemonetics and was paid $10.7M in FY2023 (Apr), up 23%.
PayNo stock prices for these years
Executives5
See all- 1Christopher A. SimonPresident and Chief Executive OfficerFY2023
- 2James C. D'AreccaExecutive Vice President, Chief Financial OfficerFY2023
- 3Michelle L. BasilExecutive Vice President, General CounselFY2023
- 4Roy GalvinExecutive Vice President, Chief Commercial OfficerNot disclosed
- 5Stewart W. StrongFormer President, Global HospitalNot disclosed
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allHaemonetics paid its 6 named executives $22.7M in total in FY2023 (Apr). CEO Christopher A. Simon was paid $10.7M of that.
| Name | |||
|---|---|---|---|
| Christopher A. SimonPresident and Chief Executive Officer | |||
| James C. D'AreccaExecutive Vice President, Chief Financial Officer | Not disclosed | ||
| Michelle L. BasilExecutive Vice President, General Counsel |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Haemonetics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board9
See all- Ellen M. ZaneChair · 7 yr on the boardIndependentGovernance and Compliance (Chair)—Paid as an executive
- Charles J. DockendorffDirector · 11 yr on the boardIndependentAudit (Chair), Governance and Compliance—Paid as an executive
- Christopher A. SimonDirector · 9 yr on the boardNot independentAudit—Paid as an executive
- Claire PomeroyDirector · 6 yr on the boardIndependentCompensation, Technology (Chair)—Paid as an executive
- Lloyd E. JohnsonDirector · 4 yr on the boardIndependentAudit, Governance and Compliance—Paid as an executive
- Diane M. BryantDirector · 2 yr on the boardIndependentCompensation, Technology—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Jun 6, 2025 | FY2025 |
| Annual report | 10-K | May 21, 2025 | FY2025 |
| Proxy statement | DEF 14A | Jun 7, 2024 | FY2024 |
| Annual report | 10-K | May 20, 2024 | FY2024 |
| Proxy statement | DEF 14A | Jun 16, 2023 | FY2023 |
| Annual report | 10-K | May 22, 2023 | FY2023 |
